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ABSTRACT 
Introduction: Type II Diabetes Mellitus is a serious metabolic disease in the world and 
it is highly associated with an increased risk of vascular complication. There are 1.9 
million people living with Diabetes in Ethiopia and DM is found to be the ninth leading 
cause of death due to its complications. Even though the rate of vascular complications 
is increasing there is limited updated information about the problem. Hence this study 
was designed to investigate vascular complications and its determinates. 
 Objective: The aim of this study was to estimate the Incidence and identify 
determinates for vascular complication among type II diabetes mellitus patients in 
university of Gondar referral hospital. 
Methodology: Institution based Retrospective follow-up study was conducted at 
University of Gondar referral hospital among 364 patients who were newly diagnosed as 
having type II DM from September 2005 up to August 2012. Simple random sampling 
technique was used to select these patients and they were followed retrospectively up 
to March 2017. The data was entered in to EPI info version 7.0 and transferred to 
STATA version 14.1 for analysis. Both bi-variable and multi variable Cox regression 
(parametric and semi-parametric) models were fitted to identify the risk factors. The best 
model was selected by using AIC, BIC and log likelihood criteria. 95% confidence 
interval of hazard ratio (HR) was computed and variables having p - value less than 
0.05 in the multivariable model were considered to be significantly associated with the 
dependent variable. 
Result: A total of 341 were followed retrospectively for a median follow up time of 81.50 
months (IQR=36.07 months). Out of all 97(28%) vascular complications was observed 
with an incidence rate of 33.81 cases/ 10000 person month observation. The cumulative 
probability of vascular complications was 0.8617 in a total of 28692.8 person month 
observations. Male sex (AHR= 0.50, 95%: 0.27, 0.94), having hypertension at 
baseline(AHR= 3.99, 95%CI: 1.87, 8.56),  , positive protein urea (AHR= 1.69, 95%CI: 
1.03, 2.78), HDL-C level ≥40mg/dl (AHR= 0.43, 95%CI: 0.24, 0.77), LDL-C level 
>100mg/dl (AHR= 3.05, 95%CI: 1.47, 6.35) and Triglyceride >150mg/dl (AHR= 2.74, 
95%CI: 1.28, 5.84) were found to be significantly associated with vascular complication. 
Conclusion: The incidence of vascular complication was relatively low. Hypertension at 
baseline, LDL-C>100mg/dl, triglyceride >150mg/dl, HDL≥40 mg/dl and male sex were 
significant predictors of vascular complication. Hence close monitoring of patients with 
hypertension co morbidity and deslipedemia should be considered. 
Key words: Incidence, Vascular complication, Type II DM, University of Gondar referral 
hospital. 
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1. INTRODUCTION 
1.1 Statement of the problem 
Diabetes mellitus is a chronic metabolic disorder characterized by chronic 
hyperglycemia and it is classified in to four major groups that are type I, type II, 
gestational diabetes and specific types of DM (1). Type II DM a serious metabolic 
diseases in the world and it is highly associated with vascular complications(2). 
Vascular complications caused by Type II DM include neuropathy, nephropathy, 
retinopathy, coronary heart dieses, peripheral arterial diseases and stroke (3). 
Globally, the prevalence of DM is 8.5 % and it is estimated one adult in 10 will have 
diabetes in the world by 2035 (4). Sub Saharan Africa countries  are expected to 
experience the worldwide fastest increase in the number of people living with type 2 
diabetes (141 %) in the next two decades (2). Ethiopia is the third most populous 
country from Africa with 1.9 million people living with diabetes (2, 5)  
The seriousness of diabetes is largely a result of its associated vascular complications, 
which can be disabling and even fatal. In 2012 there were 1.5 million deaths worldwide 
directly caused by diabetes and its complications and It was the eighth leading cause of 
death among both sexes and the fifth leading cause of death in women. Globally the 
proportion of end stage renal diseases attributable to diabetes alone ranges from 12–
55% and its Incidence is ten times higher among diabetics(4). Diabetic retinopathy 
caused 1.9% of moderate or severe visual impairment and 2.6% of blindness globally in 
2010 (6). Adults with diabetes  have a two or three times higher rate of cardiovascular 
disease like CHD, stroke and PAD than those without diabetes(7).  
In Africa the age standardized mortality rate due to diabetes and its complications is 
estimated to be 111.3 per 100000 population (4). The prevalence of diabetic 
nephropathy is estimated be 6-16% in sub Saharan Africa(8) and 6.1% in Ethiopia(9) 
and the prevalence of retinopathy ranges from 31.4%-41.1% in Ethiopia (10).  Type  II 
diabetes is rapidly increasing non-communicable diseases and major public health 
challenge in developing countries like Ethiopia(11) with consequence of chronicity and 
pre-mature death due to its vascular complications (12, 13).  In Ethiopia There were
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44,655 deaths between 2012 and 2013 among people aged 20-79 due to diabetes and 
its associated vascular complications it is also showed that diabetes was the ninth 
leading cause of death in Ethiopia with 22 per 1000 death (2, 5, 14).  
The most common factors affecting survival time to vascular complication of diabetes 
are age, sex, duration of diabetes, hypertension co morbidity(15, 16) type of 
treatment(17) and fasting blood sugar  level (18). Ethiopian diabetics association tries to 
halt the increasing trends of DM and its complications by giving screening service for 
diabetic retinopathy by provision of free medications for the patients who cannot afford 
and by preparing educational sections to create awareness about the complications and 
how to prevent them (19).  
Therefore the aim of this study was to estimate the incidence of vascular complication 
among type II DM patients As far as my knowledge is concerned there is limited study in 
this topic in the study area and we believe it will be a big input for health professionals 
and policy makers for prevention and risk minimization of vascular complications. 
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1.2 Literature review 
1.2.1 Vascular complication from type II diabetes mellitus 
Everyone who is diagnosed as having DM especially type II DM are at increased risk of 
developing Vascular complication which are classified as macro-vascular complications 
and micro- vascular complications. Macro-vascular are damages to the large blood 
vessels like peripheral arterial diseases coronary heart diseases and stork and micro 
vascular ones are damages to small blood vessels like neuropathy, nephropathy and 
retinopathy. Other possible outcomes are lost follow-up, death and being free of the 
complication at the end of the study. 
 
According to a study in India the overall prevalence of micro vascular complications is 
found to be 30.2 % and other study in the same setting estimates the prevalence of 
retinopathy, nephropathy and neuropathy to be 32.5% , 30.2% , 26.8% respectively.  
Another study in Cameroon also shows the prevalence to be 23%, 25%, 40% 
respectively (20-22). 
A retrospective cohort study done in Taiwan showed that 30.7% of the study 
participants who were free of any complication at the start of the study develop at least 
one complication during the study period and the most common first complications 
during the study are CHD, CKD and stork with a cumulative incidence after five years to 
be 6.8%, 4.5%, 2.9% respectively (23) According to other study in Japan  that used 
polled data from two clinical trials the incidence of macro vascular complications like 
CHD, stork are found to be 5.1% and 4.1% respectively and micro vascular 
complications like   nephropathy and retinopathy to be 3.7 % and 32% respectively after 
an average follow-up time of 7.2 years(16).  
According to a retrospective follow up study done in Bangladesh for 13 years: patients 
who have developed different types of complications such as coronary heart disease, 
nephropathy, diabetic retinopathy, and other (PAD, stroke and foot ulcer) were 5.2%, 
5.8%, 6.2%, and 10.8% respectively during their follow up period among the participants 
who started with no complication at the initial stage(17). 
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Other possible outcome for type II DM patients during the follow-up are Death and lost 
to follow up. A retrospective cohort study done in Asia showed 18 % and 21% of the 
patients were lost before and after they start treatment respectively and there is also 1% 
death after initiation of the treatment (24). Another retrospective follow up study 
conducted in Rwanda showed that the rate of lost follow up were  5.5%,11.5%,16.8% 
after first visit,12 months, and 24 months of follow up respectively and there were also 
1.7% and 3% death after 12 and 24 months of follow-up respectively(25).  
1.2.2 Factors affecting vascular complication from type 2 DM 
Different studies throughout the world identified different factors associated with an 
increased or decreased risk of vascular complications among diabetes mellitus patients. 
In this section we try to bring light relevant information from relating previous studies 
about socio demographic, clinical and Physiologic factors that affect time to vascular 
complication for type 2 DM patients. 
Socio demographic factors 
Multiple retrospective follow up studies in  Iran and Japan  showed that an increased 
age and male sex  are significantly associated with an increased risk of macro-vascular 
and micro vascular complications  (15, 16)  But according to other studies  in India and 
Ethiopia  females and older age are positively associated with an increased risk of 
vascular complications(18, 22). Other Meta-analysis involving 121 prospective studies 
showed that females are at increased risk of having vascular events(7).As the study in 
Bangladesh urban residents are at increased risk of having vascular complications like 
CHD than rural residents(17). 
 
Clinical factors 
According to a studies done in Iran  Japan and India hypertension and  longer duration 
of diabetes are highly associated with an increased risk of having both macro vascular 
complications like stroke, CVD and micro vascular complication like nephropathy and 
retinopathy (15, 16, 26). According to a study in Ireland type 2 DM patients with 
hypertension are at increased risk of having vascular complications (27, 28). Other 
studies in morocco and Cameroon also showed that having high blood pressure is 
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positively associated with the risk both macro and micro vascular complications 
specifically nephropathy and cardio vascular events (29, 30). A study conducted in 
Malaysia showed that patients with family history of DM have increased risk of having 
vascular complications(31) and other study in Zimbabwe showed for the  risk of diabetic 
complications to be higher among obese individuals as compared to normal weight and 
it is also showed that higher rate of chronic complications are occurred among 
unemployed patients.(32) 
According to a study in Bangladesh Oral hypoglycemic agents are associated with an 
increased risk of vascular complications like CHD and nephropathy as compared to 
insulin therapy(17). A study in North west pacific Among type 2 diabetes patients with 
an initial complication, tight glycemic control is associated with reduced risk major 
micro- vascular and macro vascular complication and additional complications in other 
organs(33, 34). A study conducted in Japan showed that Multiple insulin injections 
results a good glycemic control and significantly associated with a decreased risk of 
vascular complications(35) 
 
Physiologic factors 
According to Multi centered study that involve 28 countries from Africa, Asia and Middle 
east and other study in India; lipid profiles like LDL and HDL are significant predictors of 
vascular complications; were HDL level is negatively and  LDL level is positively 
associated with the risk of vascular complication(26, 36) and other studies in Singapore 
and Zimbabwe also showed  increased level of LDL(32) and low level of HDL(37) are 
associated with an increased risk of vascular complications and as other study in Iran 
Cholesterol and triglyceride level are positively associated with the risk of vascular 
complications(15). A study conducted in Ethiopia showed that an increased fasting 
plasma sugar level is significantly associated with an increased risk of micro vascular 
complications(18). A study conducted in India showed that an increase  ether in systolic 
or Diastolic blood pressure and Creatinine level is positively associated with a an 
increased risk of vascular complication(38)  
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Figure 1: Conceptual frame work vascular complications from type II diabetes source- 
from review of literature (16-19, 27, 35, 36) 
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1.3 Justification of the study 
Ethiopia is facing a double burden problem because Type II DM is currently increasing 
due to different factors such as aging, urbanization, increasing prevalence of obesity 
and physical inactivity and there is also an increasing trend in mortality due to its 
complications. However there are a limited number of updated information in Ethiopia 
and in the study area that documented time to vascular complication. This study  have 
used advanced Parametric survival models to Identify significant factors that affect time 
to vascular complication for type II DM patients. This study could provide information for 
health professionals, policy makers and other governmental and none governmental 
organizations to maximize efforts on prevention and risk minimization of vascular 
complication and deaths due to the complication in the country as well as in the study 
area. In addition to this it could be used as a reference for other researchers. 
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2. OBJECTIVES 
 
2.1 General objective 
 
The objective of this study was to estimate the incidence and identify determinates of 
vascular complication among type II Diabetes mellitus patients in University of Gondar 
referral hospital. 
 
2.2 Specific objective 
 
✓ To estimate the incidence of vascular complication among type II Diabetes 
mellitus patients in University of Gondar referral hospital. 
✓ To identify determinates for vascular complication among type II Diabetes 
mellitus patients in University of Gondar Hospital. 
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3. METHODOLOGY 
3.1 Study design and period 
Institution based retrospective follow up study was conducted from September 2005  
up to March 2017 among type II DM patients in university of Gondar referral hospital. 
3.2 Study setting 
The study was conducted in University of Gondar referral hospital among type II DM  
patients. The hospital was established 1954 and it is located in North Gondar  
administrative zone, Amhara National Regional state, which is far about 750 km  
Northwest of Addis Ababa (the capital city of Ethiopia). According to the 2015  
population projection of major cities in Ethiopia the total population size of Gondar town 
 was estimated to be 323,900 Currently, Gondar town has one Referral Hospital and  
eight government Health Centers. University of Gondar Referral Hospital is a teaching  
Hospital which serves more than five million people of the North Gondar zone and  
peoples of the neighboring Zones. Around 24,552 number of people are having chronic  
follow-up per year and among this 8,880 are DM patients. 
3.3 Source and study population 
The source population for this study were  type II diabetes patients having a follow up at 
university of Gondar referral hospital and the study population were all newly diagnosed 
type II diabetes patients in university of Gondar referral hospital from September 2005 
to August 2012. 
3.4 Inclusion and Exclusion criteria 
All Newly diagnosed type II DM patients between September 2005 and August 2012 
were included; however newly diagnosed patients who had any of the vascular 
complications at the start of the study and patients who had missing on the key 
variables were excluded from the study. 
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3.5 Sample size and sampling procedure 
We have used a two step processes to determine the sample size the first one is 
determining the total number of expected event (vascular complications) and  the 
second one is the  total sample size required to get this number of events (vascular 
complications) and its given by(39).   
Step 1-   M= 
(𝑍𝛼 2+𝑍𝛽)^2⁄
Ө
2
П(1−П)
 
Were - M is number of expected events (vascular complications) 
          - 𝑍 𝛼 2⁄  𝑎𝑛𝑑 𝑍𝛽 are reliability coefficients based on α and β respectively. 
          - Ө is logarithm of the hazard ratio. 
          - П is the fraction of subjects allocated to the first group. 
Step 2-  n =  
𝑀
𝑝(𝑒𝑣𝑒𝑛𝑡)
 
Were - n is the number of subjects to be followed. 
           M is the number of events  
           P is the over all probability of an event (vascular complication) at the end of the 
study.       Therefore based on the results we found from previous retrospective follow 
up studies done in Asia and Ethiopia (15, 16, 18, 23) we had the following sample. 
Table 1: Sample size determination 
Assumptions Predictors Hazard ratio Sample 
size(Event) 
Power=80%                 α=0.05 
П =0.5                    P(event)=0.31                          
Withdrawal=10%          β=0.2                        
BMI (normal weight) 0.67 364(202) 
Sex(Female) 1.53 262(180) 
HTN(yes) 1.80 138(98) 
 
So the sample size was 364 with the estimated number of events to be 202 and these 
subjects were selected based on simple random sampling from all newly diagnosed 
patients in the recruitment period. 
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3.6 Variables in the study 
Dependent variable 
Time to vascular  complication. 
Independent variables 
Socio demographic- Age, Sex, Residence, Occupation 
Clinical- Type of treatment, family history of DM, Hypertension, Body mass index 
Physiologic factors- Low Density Lipoprotein level, High Density Lipoprotein level, 
Protein urea, Creatinine, Triglycerides, Cholesterol, Fasting Blood Sugar, Systolic blood 
pressure, Diastolic blood pressure. 
 
3.7 Operational Definitions 
Vascular complication- The first event from any of the vascular complications 
associated with DM like coronary heart diseases, peripheral arterial diseases, stork, 
retinopathy, nephropathy and neuropathy. 
Censored- Includes lost to follow up, death and being event free at the end of the 
study. 
Lost follow up- Patients not having visited the clinic at least for one year. 
Time to vascular complication- The length of time in month from the start of treatment 
up to the development of any of the vascular complications. 
Systolic blood pressure, Diastolic blood pressure, Creatinine, Fasting blood 
sugar, high density lipoprotein, low density lipoprotein, Triglyceride, total 
cholesterol and treatment type – The most recent measurements just before the 
complication or censoring time.  
3.8 Data collection procedures 
Data collectors: Data extraction check list was prepared in English. Two health officers 
have collected the data and it is supervised by one person with a qualification of Master 
of public health.  
Data collection procedure:  The records to be reviewed were identified by their 
medical registration/card number. Then, together with the data clerk working at DM 
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follow up clinic of the hospital, data collectors had reviewed and extract data from 
patient charts and registries. 
 
Data quality Assurance 
The quality of data was ensured through training of data collectors and supervisor, close 
supervision and prompt feedback. The training consisted of instruction on extracting 
techniques, as per data extraction format. The data were checked for any 
inconsistencies, coding error, out of range, completeness, accuracy, clarity, missing 
values and appropriate corrections was made by the principal investigator and the 
supervisor consistently on the daily basis.    
3.9 Data processing and analysis 
3.9.1 Data processing 
The data were reviewed from completed structured data retrieval form to ensure 
completeness and quality of data. After data quality was assured, forms were collected 
and assigned consecutive number (code) for ease of data entry. The Data was entered 
using the Epi-Info version 7.0 and clean-up has been made to check accuracy, 
consistency and errors identified were corrected. After the data was checked for correct 
entry, it was exported to STATA 14.1 software for analysis. Further data cleaning and 
frequency run was made to check the accuracy, consistencies missed values and 
variables. Cross tabulations and summary statistics were used to describe the study 
population in relation to relevant variables. 
3.9.2 Data analysis 
3.9.2.1 Descriptive statistics in Survival analysis 
Let T be the survival time and C the censoring time. Define the follow-up time Y=min (T, 
C), and let 𝛿 denote the censoring indicator. Considering the probability density function 
of T, f(t) =P (T≤ t) = lim
∆𝑡⇾0
𝑝𝑟(𝑡≤𝑇<𝑡+∆𝑡)
∆𝑡
, which represents the unconditional probabilities of 
developing vascular complication, the survival function is defined as the complement of 
the cumulative distribution function, S(t)= P(T>t) giving the probability that the event has 
occurred after duration t and its non–increasing function. An alternative characterization 
of the distribution of T is the hazard function which is the instantaneous probability of 
13 
 
having an event at time t (per unit time) given that one has survived (i.e. Not had an 
event) up to time t and it’s given as: 
                               λ(t) = lim
∆𝑡⇾0
𝑃(𝑡≤𝑇<𝑡+∆𝑡/𝑇≥𝑡)
∆𝑡
 
           
 Estimation of Survival function 
In practice, when using actual data, we usually obtain estimated survivor function and 
obtain curves that are step functions, rather than smooth curves. 
Kaplan-meier estimator 
This is a non-parametric estimator of survival function proposed by Kaplan and Meier 
(1958) It incorporates information from all of the observations available, both censored 
and uncensored, by considering any point in time as a series of steps defined by the 
observed survival and censored times. 
Let t1, t2,…,tn be the survival time of n independent observations and  
t(1)≤t(2)≤…≤t(m), m≤n be the m distinct ordered vascular complication times . The 
Kaplan-Meier estimator of the survivorship function (or survival probability) at time t,  
s(t) = p(T≥t) 
Skm(t) = П𝑡(𝑖) < 𝑡 (
𝑛𝑖−𝑑𝑖
𝑛𝑖
) 
Where; t(i) = Distinct ordered times of vascular complication  
             di  =  The number of events at time t(i) 
             ni = The number of individuals still at risk right before ith event time  
The Kaplan-Meier estimator is a step function with discontinuities or jumps at the 
observed event times, coinciding with the empirical survival function if there is no 
censoring(40) 
Comparisons of survival curves 
In clinical research we are both concerned on estimating the survival function and, 
comparison of the life experience of two or more groups of Subjects differing for a given 
characteristic or randomly allocated to different treatments. Nowadays, the Kaplan-
Meier method for estimating survival curves which plotting the corresponding estimates 
of the two survivor functions on the same axes of Kaplan-Meier estimator and the log-
rank test for comparing two estimated survival curves are the most frequently used 
statistical tools in medical reports on survival data. 
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Log-rank test 
The log rank test, developed by Mantel and Haenszel, is a non-parametric test for 
comparing two or more independent survival curves. Since it is a non-parametric test, 
no assumption about the distributional form of the data is required. The log rank test 
statistic for comparing two groups is given by:    
                                        QLR = 
[∑ (𝑑1𝑖−𝑒1𝑖)]^2𝑚𝑖=1
∑ 𝑣1𝑖𝑚𝑖=1
 
Were; m = Rank ordered event (vascular complication) times 
          d1i= Observed number of event (vascular complication) in group one at event   
  time ti 
          e1i=  Expected number of event (vascular complications) corresponding to d1i  
                   and it is  given by 
𝑛1𝑖−𝑑𝑖
𝑛𝑖
   were n1i the number of individuals at risk in group  
                   1just prior to the event time ti , di the number of events (vascular 
                   complication) in both group, ni number of individuals at risk in both group. 
          v1i= variance of the number of events di at time ti  and it is given by   
𝑛1𝑖𝑛𝑜𝑖𝑑𝑖(𝑛𝑖−𝑑𝑖)
𝑛𝑖2(𝑛𝑖−1)
    
                 were ni and di are the number of individuals at risk and number of   (vascular 
complication) in both groups just prior to event time ti respectively.              
Under the null hypothesis that two survival functions are equal, the log rank test statistic 
Q has an approximation of chi-square distribution with one degree of freedom for large 
samples. The null hypothesis of equality of survival functions will be rejected for large 
value of Q (39). 
3.9.2.2 Regression models for survival data 
In most medical studies which give rise to survival data, supplementary information 
referred to as covariates or independent variables needs to be collected on each 
individual, so that the relationship between survival experience of individuals and 
various explanatory variables have to be investigated. 
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Cox Proportional Hazard model 
The Cox Proportional Hazard (PH) Model is a multiple regression method and is used to 
evaluate the effect of multiple covariates on the survival.  It is semi parametric model for 
the hazard function that allows the addition of covariates, while keeping the baseline 
hazards unspecified and can take only positive values and it is defined as 
                                          h(t, x, β )= ho(t) eβ'x 
were h(t, x, β ) the hazard function at time t with a covariates X=(x1,x2,…,xp)' 
ho(t) the arbitrary baseline hazard function that characterizes how the hazard function 
changes as a function of time. 
β= ( β1, β2,…,βp) is a column vector of p regression parameters associated with 
explanatory variables. 
e β'x characterizes how the hazard function changes as a function of subject covariates 
t is failure time 
Each individual has its own hazard function of survival time. Then, the above model 
becomes 
h(t,xi,β) = ho(t)exp(β1xi1+ β2xi2+…+ βpxip), I =1,2,…,n 
were n is total number of observations in the study. 
         Xi= (xi1 ,xi2 ,..,xip)'  is a column vector of measured covariates for the ith 
          Individual (patient) which are assumed to affect the survival probability. The 
         assumptions of Cox proportional hazard model are: 
-The baseline hazard function ho(t) depends on t , but not on covariates x1, x2…,xp  
- The hazard ratio, depends on the covariates x=(x1,x2,…,xp)' not on time. 
-The covariates xi are time independent 
Parametric survival models 
Parametric survival models make assumptions about the distribution of failure times and 
the relationship between covariates and survival experience and they fully specify the 
distribution of the baseline hazard/survival function according to some (defined) 
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probability distribution. Examples of distributions that are commonly used for survival 
time are: the Weibull, exponential, log-logistic, lognormal, Gompertz, and generalized 
gamma. 
✓ Exponential Distribution 
The exponential distribution is the only distribution with a constant hazard i.e λ (t, λ)= λ, 
λ>0 This implies that the conditional probability of an event is constant over time. In 
other words, the risk of an event occurring is flat with respect to time. The survival 
function is S(t, λ)= e-λt  it can be shown that E(T)=1/ λ and var(T)=1/ λ2. 
✓ Weibull Distribution 
The Weibull model is more general and flexible than the exponential model and allows 
for hazard rates that are non-constant but monotonic. It is a two-parameter model (λ 
and ρ), where λ is the location(scale) parameter and ρ is the shape parameter ρ 
determines whether the hazard is increasing, decreasing, or constant over time. The 
shape parameter works in the following way: 
▪ If 0< ρ <1, then the hazard is monotonically decreasing with time.  
▪ If ρ=1, then the hazard is flat and we have the exponential model i.e. the Weibull 
model nests the exponential model. This means that we can use the Weibull 
model to test if the exponential model is appropriate.  
▪ If ρ>1, then the hazard is monotonically increasing with time.  
✓ Gompertz Distribution  
A random variable T has the Gompertz distribution with the following hazard and 
survivorship functions λ (t, λ, ρ) = λ exp (ρt),  s(t, λ, ρ)= exp(
λ
ρ
(1 − exp(ρt))) respectively. 
where the scale parameter λ>0, and shape parameter ρ ϵ(-∞, +∞). 
If ρ>0, then the hazard exponentially increases over time. If ρ<0 then the hazard 
decreases exponentially over time. If ρ =0then the hazard is constant and reduces to 
the exponential model. 
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3.9.2.3 Model comparison 
Model comparison and selection are among the most common problems of statistical 
practice, with numerous procedures for choosing among a set of models(41) There are 
several methods of model selection. The most commonly used methods include 
information criteria’s(AIC, BIC) and likelihood based criteria and in this case we have 
used these three methods  to make comparison  between the candidate models. 
                          AIC= -2L(Ө) + 2npar 
                                   BIC= -2L(Ө) + nparlog n 
These criteria’s are used for non nested models and the model is Saied to be best 
model if it has the smallest AIC or BIC value (42). 
3.9.2.4 Goodness of fit test 
The use of diagnostic procedures for model checking diagnostics is an essential part of 
the modeling process. 
Cox Snell residual 
For all regression models, a specifically designed statistic to evaluate the accuracy of a 
postulated model (goodness-of-fit) is called a residual value. Residual values reflect the 
difference between the model-estimated values and the observed data that generated 
the model estimates. A simple transformation of the survival function S(t) yields Cox 
Snell  residual values which is given by  
                           ri= − log[𝑆𝑜(𝑡𝑖)] 
The Cox–Snell residual values have none of these properties. Their mean value and 
variance depend on the number of randomly censored observations, they take on only 
positive values, and they typically have an asymmetric distribution. When a model “fits” 
the data, the residual values are likely small and certainly randomly distributed When a 
model fails to “fit” the data in some systematic way, at least some of the residual values 
are likely large and nonrandom (43) 
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each client rather it was informed to the head of hospital manager. Privacy of the 
patients were maintained, Names were not included, and questionnaires kept locked 
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5. RESULTS 
5.1. Socio-demographic, Clinical and Physiologic Characteristics of Study 
Participants  
    
In this study a total of 364 newly diagnosed type II DM patients were included but 23 
(6.3%) subjects were excluded because of the missing of key variables like HDL-C, 
LDL-C, cholesterol and time of the start of treatment. A total of 341 patients were 
included in the analysis.  
Majority of the study participants were females accounting 196 (57.48%) of the total 
sample. About 273(80.06%) of the study participants were urban dwellers. Majority of 
the patients 149(43.7%) included in the study was unemployed 149(43.7) followed by 
Government workers which was 88(25.81%) of the total sample. About 228(66.86%) of 
the patients had family history of DM   a More than half of the patients 183(53.67%) had 
hypertension at the start of anti-type II DM treatment. Almost half of the type II DM 
patients enrolled in the study were having normal weight and 45(13.2%) were obese. 
About 230(67.45%) were on OHA and Majority of the patients 271(79.47%) had positive 
protein urea at base line.  
About 234(68.62%) of the patients had HDL-C level above 40 mg/dl and more than half 
of the patients (54%) had LDL-C level less than 100mg/dl. More than half of type II DM 
patients included in the study 178(52.2%) had triglyceride level ≤150mg/dl and around 
211(61.88%) of the patients were having a cholesterol level ≤200mg/dl.  
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Table 2: Socio-demographic, clinical and Physiologic   characteristics of Type II DM 
patients on anti diabetic’s treatment at university of Gondar referral hospital, September, 
2005 – March 2017. 
Variable Frequency Percent 
Sex 
     Female 
     Male 
 
196 
145 
 
57.48% 
42.52% 
Residence 
     Rural 
     Urban 
 
68 
273 
 
19.94% 
80.06% 
Occupation 
     Unemployed  
     Government 
     NGO 
     Private 
 
149 
88 
20 
84 
 
43.7% 
25.81% 
5.87% 
24.63% 
Family history 
     Yes 
     No 
 
228 
113 
 
66.86% 
33.14% 
Hypertension 
     No 
     Yes 
 
158 
183 
 
46.33% 
53.67% 
BMI 
    <18.5 
    18.5- 24.99 
    25- 29.99 
    ≥30 
 
29 
169 
98 
45 
 
8.5% 
49.56% 
28.74% 
13.2% 
Treatment 
    OHA 
    Insulin 
    OHA + Insulin 
 
230 
64 
47 
 
67.45% 
18.77% 
13.78% 
Protein urea 
    Negative 
    Positive 
 
271 
70 
 
79.47% 
20.53% 
HDL 
   <40 mg/dl 
   ≥40 mg/dl 
 
107 
234 
 
31.38% 
68.62% 
LDL 
   ≤ 100 mg/dl 
   >100 mg/dl 
 
186 
155 
 
54.55% 
45.45% 
Triglyceride 
    ≤150 mg/dl 
    >150 mg/dl 
 
178 
163 
 
52.2% 
47.8% 
Cholesterol 
    ≤200 mg/dl 
    >200 mg/dl 
 
211 
130 
 
61.88% 
38.12% 
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The mean age for patents at the start of treatment was found to be 51.7(SD=11.5 years) 
and it ranges from 20 up to 87 years. Patients were followed for median of 81.50 
months (IQR=36.07 months) and the maximum time the patient followed was 140.43 
months. The median value for Creatinine 0.78(IQR=0.23 ml/s), 
FBS146mg/dl(IQR=77mg/dl), SBP 125mm/hg(IQR=20mm/hg)  and DBP 80mm/hg(IQR 
20mm/hg).   
Table 3: Summary statistics of continuous variables included in the study of type II DM 
patients under Anti diabetic’s drug at university of Gondar referral hospital, September, 
2005 – March 2017. 
Status of a Patient Variable  Min Max Median IQR 
Censored        Time 11.20 140.43 84.15 37.58 
       Age 20 87 50 50 
       Creatinine 0.13 1.86 0.76 0.21 
       FBS 75 347 136 48 
       SBP 90 180 120 20 
       DBP 60 110 80 10 
Vascular 
complication 
      Time 8.07 136.20 69.80 42.10 
      Age 35 82 55 55 
      Creatinine 0.12 5.26 0.83 0.45 
      FBS 28 460 200 97 
      SBP 100 200 140 20 
      DBP 65 100 90 10 
Overall      Time 8.07 140.43 81.50 36.07 
      Age 20 87 50 16 
     Creatinine 0.12 5.26 0.78 0.23 
     FBS 28 460 146 77 
     SBP 90 200 125 20 
     DBP 60 110 80 20 
 
5.2. Vascular complication from type II DM 
Study subjects were followed for different period of time with a median of 81.50  months 
(IQR=36.07 months)  the minimum time the patient was followed is 8.06 months and the 
maximum time was 140.43 months after the start of treatment. Based on this the total 
person time observation was found to be 28692.8 person months. During the follow up 
period a total of 97(28%) newly diagnosed patients who were free from any 
complication at the start of their treatment have developed at least one of the vascular 
complications. 
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Figure 2: Pie chart showing the proportion of event and censored patients among type II 
DM patients in university of Gondar referral hospital from September 2005 March 2017. 
Out of a total of vascular complications the largest proportion 38(38.54%) was found to 
be neuropathy followed by nephropathy 26(27.8%), stork 8(8.83%) retinopathy 
7(7.29%) and equal number of subjects 9(9.38%) have developed CHD and PAD. 
 
 
Figure 3: Frequency distribution of the type of vascular complications among type II DM 
patients on anti-diabetics treatment at university of Gondar referral hospital, September, 
2005 – March 2017. 
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The incidence of vascular complications was found to be 40.6 cases (95% CI:,33.2, 
49.5) per 1000 person year observation and from this the incidence of retinopathy was 
18.4 (95% CI: 8.8, 38.6), nephropathy 14.4(95% CI: 9.8, 21.4), neuropathy 18.9(95%CI: 
13.7, 25.9), stork 17.0(95%CI: 8.5, 33.9), CHD 16.7(95%CI: 8.7, 32.1) and PAD 
15.1(95%CI: 7.9, 29.0)  cases per 100 person year observation.   
The cumulative probability of developing vascular complication among Type II DM 
patients who were free from any of the complications at the start of the treatment   was 
0.0423 at month 40, 0.1653 at month 70, 0.3726 at month 100, 0.5587 at month 120 
and 0.8617 at month 140 during the follow up time.  The median survival time was 
found to be 110.5 months (fig 4). 
 
Figure 4: The Nelson-Aalen estimated cumulative curve showing cumulative probability 
of vascular complication among type II DM patients on anti diabetic’s treatment at 
university of Gondar referral hospital, September, 2005 – March 2017. 
5.3. Predictors of vascular complication among type II DM patients  
A separate graph of estimates of Kaplan meier survival functions had been constructed 
for different categorical variables. By doing this it was possible to see the existence of 
difference in survival experience between individuals of the indicated categories. In 
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general the pattern of the survivorship function lying above another means the group 
defined by the upper curve has a better survival than the group defined by the lower 
curve. The Kaplan mere survival function plot for all categorical variables was 
done(Appendix 4, fig A-L) From this type II DM patients who had hypertension at 
baseline have less survival than patients who had no hypertension (fig 5). 
 
 
Figure 5: Kaplan Meir survival curve showing hazard of vascular complication by 
hypertension status at baseline among type II DM patients on anti diabetic’s treatment in 
university of Gondar referral hospital, September, 2005 – March 2017. 
The log rank statistical method was used to check whether there is a significant 
difference in the  survival functions among categories that is shown using Kaplan meier 
estimates of survival functions. Based on the result of log rank test there were a 
significant difference in survival among categories of sex, occupation, protein urea, 
HTN, HDL-C, LDL-C, triglyceride, cholesterol and BMI. However there is no significant 
difference among categories of residence and treatment type. 
Type II DM patients who have no history of hypertension at the start of diabetes 
treatment had longer survival experience than Type II DM patients with history of 
hypertension which is supported by log rank test( log rank Chi2(1)=72.7, p-value=0.000) 
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Type II DM patients with Negative  protein urea at the start of diabetes treatment has a 
better survival experience than that of type II DM  patients with positive protein urea  
which is supported by log rank test (log rank Chi2(1)= 52.91, p-value=0.0000 
Table 4: Results of the Log-rank test for the categorical variables of type II DM patients 
on anti diabetic’s treatment in university of Gondar referral hospital, September, 2005 – 
March 2017. 
covariate df Chi-square P-value 
Sex 1 12.01 0.0005 
Residence 1 1.76 0.1851 
Occupation 3 15.85 0.0012 
Protein urea 1 52.91 0.0000 
Treatment 2 0.72 0.6964 
HTN 1 72.7 0.0000 
HDL 1 113.9 0.0000 
LDL 1 106.08 0.0000 
Triglyceride 1 66.86 0.0000 
Cholesterol 1 54.51 0.0000 
BMI 3 32.33 0.0000 
 
Assessing the proportional hazard assumption 
In order to fit a model we have to asses some requirements of the model that means the 
model should be assessed whether it describe our data well or not. In this case the 
main aim is testing the proportional hazard assumption and measuring the overall 
goodness of fit of the model. The proportional hazard assumption states that the risk of 
failure of the study subjects must be the same no matter how long they are followed.  
The plot of log [- log (survival probability) versus log of survival time was done for 
different categories of predictor variables (Appendix 6, fig A-G). As it is observed from 
the plot of two categories of sex and LDL-C the two lines were nearly parallel which 
means that the proportional hazard assumption was valid.(fig 6)  
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Figure 6: Plot of log (-log(survival probability)) Vs log (survival time) by LDL-C and sex 
for type II DM patients on ant diabetics treatment at university of Gondar referral hospital 
September,2005-March 2017. 
The interaction of each of the covariates with time was also assessed and all of time 
dependent interactions was not significant (Appendix 3, Table 1).  
The global test of proportional-hazards assumption based on the Schoenfold residuals 
was also done and It was found that all of the covariates and full model satisfies the 
proportional hazard assumption (Chi square= 16.37, p-value= 0.5102) (Appendix 3, 
Table 2) 
In the process of model development, it is relevant to check whether the correct 
functional form of a continuous covariate that is/are included in the multivariable model 
was used. Based on this the assumption of linearity is fulfilled for Age, Creatinine, 
Fasting blood sugar, Diastolic blood pressure, and Systolic blood pressure. 
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Model comparison 
After proportional hazard assumption was checked both semi-parametric and 
parametric proportional hazard models were fitted to estimate the survival time to 
develop vascular complications and identify predictors among type II DM patients. the 
most parsimonious mode were chosen by using information criteria’s(AIC, BIC) and Log 
likelihood. 
Based on all the three comparison techniques used the Gompertz regression model( 
AIC=277.7724, BIC=369.7376, log likelihood=-114.8862)  was found to be more 
efficient than Cox-PH and other parametric models. Following this all two and three way 
interaction terms were checked to assess their importance in predicting time to vascular 
complication. However, none of them had significant contribution. Interpretations and 
conclusions were thus be based on Gompertz model.  
 
Table 5: Summary of Model comparison between semi-Cox proportional hazard models 
and parametric Cox- Regression models using AIC, BIC and log likelihood 
Comparison methods                                      Models 
 Cox PH model Exponential Weibull Gompertz 
Log likelihood  -408.4529 -167.57514 -115.9195 -114.8862 
AIC 860.9258 381.1515 279.8319 277.7724 
BIC 945.2272 469.2848 371.7971  369.7376 
 
After fitting a univareate Gompertz proportional hazard model all the predictor variables 
were found to have p-value <0.2 after this a multivariable model were fitted and 
covariates like Sex, Hypertension status at baseline, protein urea at baseline, HDL-C 
level, LDL-C, Triglyceride level were found to be significant predictors for time to 
develop vascular complication among type II DM patients at 5% level of significance.  
The hazard of developing vascular complication is decreased by 50% among male type 
II DM patients than female type II DM patients keeping other variables constant. (AHR= 
0.50, 95%: 0.27, 0.94) 
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The hazard of developing vascular complication is increased by 69% among type II DM 
patients with positive protein urea than patients with negative protein urea keeping other 
variables constant. (AHR= 1.69, 95%CI: 1.03, 2.78)  
The hazard of developing vascular complication for patients with type II DM who have 
hypertension at baseline is 3.99 times the hazard of patients who have no hypertension 
at baseline keeping other variables constant.(AHR= 3.99, 95%CI: 1.87, 8.56)  
The hazard of developing vascular complication is decreased by 57% among type II DM 
patients with high HDL level (≥ 40 mg/dl) than patients with low  HDL-C level (<40mg/dl) 
keeping other variables constant.(AHR= 0.43, 95%CI: 0.24, 0.77)  
The hazard of developing vascular complication type II DM patients with high LDL-C 
level (>100 mg/dl) is 3.05 times the hazard of patients with low LDL level (≤100 mg/dl) 
keeping other variables constant.(AHR= 3.05, 95%CI: 1.47, 6.35)  
The hazard of developing vascular complication among type II DM patients with high 
triglyceride level (>150mg/dl) is 2.74 times the hazard of patients with low triglyceride 
level (≤150mg/dl). (AHR= 2.74, 95%CI: 1.28, 5.84)  
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Table 6: Multivariable analysis using the Gompertz Cox-Regression model for predictor’s 
vascular complication among type II DM patients in university of Gondar referral hospital 
September, 2005 – March 2017. 
 
 
Variable 
     Survival Status     Crud HR 
    (95% CI) 
Adjusted HR  
(95% CI) Event Censored 
     
Age   1.04(1.03, 1.06) 1.02   (0.99,  1.04) 
Sex      
          Female 68 128 1 1 
          Male 29 116 0.47(0.31, 0.73) 0.50(0.27, 0.94)* 
Residence     
         Rural 14 54 1 1 
         Urban 83 190 1.47(0.84, 2.60) 0.51(0.25, 1.02) 
Occupation     
        Unemployed 57 92 1 1 
        Government 17 71 0.80(0.41,1.57) 0.796(0.41, 1.56) 
        NGO 4 16 0.38(0.14,1.05) 0.85  (0.27, 2.70) 
        Private 19 65 0.52(0.31,0.88) 0.83 (0.39, 1.74) 
Family history     
        Yes 50 178 1 1 
        NO 47 66 2.17(1.45, 3.23) 1.25  (0.78, 2.01) 
 
Treatment Type 
    
        OHA 67 163 1 1 
        Insulin 16 48 0.79(0.45, 1.36) 0.50(0.28, 1.01) 
        Insulin + OHA 14 33 0.87(0.46, 1.67) 0.91(0.48, 1.72) 
BMI     
       18.5 – 24.99 32 137 1 1 
       <18.5 5 24 0.82(0.32, 2.10) 1.07(0.34, 3.27) 
       25-29.9 36 62 2.04(1.27, 3.29) 0.66(0.37, 1.16) 
       ≥30 24 21 4.22(2.47, 7.21) 0.84(0.44, 1.61) 
HTN status     
       No HTN 10 148 1 1 
       HTN 87 96 10.57(5.48, 20.38) 3.99(1.87, 8.56)*** 
SBP   1.03(1.0, 1.04) 0.995(0.97, 1.01) 
DBP   1.07(1.05, 1.09) 1.02(0.99, 1.05) 
 
HDL-C 
    
       <40mg/dl 71 36 1 1 
       ≥40mg/dl 26 208 0.12(0.07, 0.18) 0.43(0.24, 0.77)** 
LDL-C     
       ≤100mg/dl 12 174 1 1 
       >100mg/dl 85 70 13.12(7.14,24.10) 3.05(1.47, 6.35)** 
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Cholesterol level  
       ≤200mg/dl 27 184 1 1 
       >200mg/dl 70 60 4.67(2.99, 7.28) 0.76(0.43, 1.36) 
Triglyceride     
        ≤150mg/dl 13 165 1 1 
        >150mg/dl 84 79 8.08(4.50, 14.49) 2.74(1.28, 5.84)** 
FBS   1.008(1.006,1.010) 1.00(0.999,1.005) 
Creatinine   1.003(0.995,1.010) 100(0.995, 1.009) 
Protein urea     
        Negative 54 217 1 1 
        Positive 43 27 4.14(2.77, 6.19) 1.69(1.03, 2.78)* 
LR  test chi2(22)  =  202.07                                           Prob > chi2   =  0.0000 
*** p-value<0.001                     **p-value<0.01              *p-value<0.05 
 
The shape parameter gamma was found to be 0.37 (95% CI:0.29, 0.44) which is 
positive. This indicates that the hazard of vascular complications increases 
exponentially with time.  
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Goodness of fit test  
The Cox- Snell residuals (together with their Nelson-Aalen cumulative hazard function) 
had been obtained from fitting using the exponential, Weibull, Gompertz models to our 
data (Appendix 5). It can be seen that the plot of the Nelson Aalen cumulative hazard 
function against Cox-Snell residuals is closest to 450 straight line through the origin for 
Gompertz model when compared to Weibull and Exponential. This suggests that the 
Gompertz model provided the best fit for our data set (fig 6). 
 
Figure 7: Cox-Snell residual obtained by fitting Gompertz model for type II DM patients 
under ant diabetic’s treatment in University of Gondar Referral hospital September, 2005 
–March 2017. 
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6. DISCUSSION 
This study mainly investigated the incidence and determinates of vascular complication 
among type II DM patients in university of Gondar referral hospital, Ethiopia. Many other 
studies reported different risk factors for vascular complication; our study also assessed 
socio-demographic, clinical and physiologic characteristics of the patients based on the 
records from their medical follow up chart. As a result factors like male sex, having 
hypertension at baseline, positive protein urea, HDL-C level ≥40mg/dl, LDL-C level 
>100mg/dl and Triglyceride >150mg/dl were found to be significantly associated with 
vascular complication.  
During the study period the cumulative incidence of vascular complications after a 
median follow up time of 6.8 years were 28%. This result was a little bit lower than the 
study done in Taiwan (23) which showed the Incidence to be 30.7% after a median 
follow up time of five years. In this we found the incidence rate to be 40.6 cases per 
1000 person year observation. The incidence of CHD and Stroke was found to be 16.7 
and 17.0 cases per 100 person year observation in our study;  this was also lower than 
a study in India(44) which showed the incidence rates to be 216 and 115 cases per 
1000 person year observation respectively. The incidence rate of retinopathy was  18.4 
cases per 100 person year observation was also lower than other study done in 
Kenya(45) which showed the incidence to be 224.7 cases per 1000 person year 
observation. This could be due to the difference in median follow-up time (India=13 
years), age of the study participants because the study in Kenya used patients above 
the age of 50 and the difference  could also be due to the difference in  diagnostic 
methods  used By the studies.    In contrast to this  the incidence of retinopathy (18.4) 
nephropathy(14.4) neuropathy(18.9) and PAD(15.1) cases per 100 person year 
observation were found to be higher than other study in India(46) which showed the 
incidence of retinopathy, nephropathy, neuropathy and PAD to be 78, 58, 13.9, 2, 5.4 
cases per 1000 person year observation. This could be due to and short follow up 
time(5.7 years) used by the Indian study.   
In our study male type II DM patients accounted only 29.9% of the events and they were 
found to have lower risk of developing vascular complication than female patients. This 
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is in line with three  studies done in Ethiopia (18), India(47) and  met analysis (7) which 
showed female patients to have higher risk to develop vascular complications. This 
could be due to the hormonal differences because female patients encounter hormonal 
imbalance or decreased estrogen level at menopause and at the same time they lose 
the vasodilatory and anti-inflammatory activity of estrogen and this will lead to 
endothelial dysfunction(48). Other reason could be due to sex specific factors like 
polycystic ovarian syndrome, preeclampsia and gestational DM(49).Other possible 
reason could be high exposure of males for physical activities. Because Physical activity 
contributes to improve insulin sensitivity and to decrease blood glucose level and weight 
loss(50). In contrast to our result other retrospective follow up studies done in Iran(15) 
and Japan(16) showed males to be at increased risk of developing  vascular 
complications. Therefore there is a need of further research to determine if this sex 
difference contributes to the better outcomes in man with diabetes.   
In our study it was found that type II DM patients who had hypertension at base line had 
an increased risk of developing vascular complications. This result is consistent with 
other studies done in Iran(15), Japan(16), India(26), and Ireland(28) which showed 
having hypertensions puts the patients at higher risk for both macro and micro vascular 
complications. Some other studies In Cameroon and morocco investigated the 
association between hypertension and specific complications; in this regard Type II DM 
patients with hypertension were at increased risk of nephropathy and cardio vascular 
events (29, 30). The possible reason could be the hypertension can affect endothelial 
cell structure and functioning that leads to enhanced growth and vasoconstriction; this 
changes to the endothelium has a key role in the development of arthrosclerosis and 
glomerulosclerosis this finally predispose patients for vascular complications(51).  
In this study increased Triglyceride level>150mg/dl and LDL-C level>100mg/dl were 
found to increase the risk of vascular complication but HDL level ≥ 40mg/dl was 
associated with decreased risk of vascular complications.  This result was in 
accordance with other studies done in India (21),Singapore (37), Zimbabwe (32) and 
multi-centered study involving 28 countries from Asia Africa Europe and south America 
(36).  These four studies showed that patients with higher levels of LDL- cholesterol to 
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have higher risk to develop vascular complication but patients with the higher levels of 
HDL-cholesterol have decreased risk. Our result was also consistent with Other study in 
India which showed increased level of triglycerides to increase the risk of developing 
vascular complications like stroke and CHD(44). This could be due to their function. 
Since the function of HDL cholesterol is transport of fats (lipids) Away from the artery 
wall to the liver this eventually reduces risk of accumulation fats and arthroscleroses 
within the arterial wall and at the same time it protects the inner wall of the arteries from 
damage so this reduces the risk of CHD, Stork and other vascular diseases (52). The 
reverse is true for LDL cholesterol because LDL -C transports fates (lipids) to the 
arteries which in turn produce arthrosclerosis in the arteries so this increases the risk of 
vascular complication(53). Excess level triglycerides above the normal range 
(>150mg/dl)   also produces plaque in the arteries so it increases the risk of vascular 
complications. In our study it was found that patients with positive protein urea have an 
increased risk of having vascular complication this may be due that protein urea is an 
early sign to the damage for kidneys so patients with positive protein urea are at 
increased risk of vascular complications like nephropathy in the long run(54). 
The clinical importance of this study was to provide information for health professionals 
and patients about factors that are associated with the risk of vascular complication and 
to act on them to minimize the risk and maximize their effort on prevention of having the 
problem and the public health importance of this study is the to prevent economic loss 
associated with the diseases and its complications. 
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7. STRENGTH AND LIMITATION 
Strength of the study 
 Patents were followed for long duration with a maximum of 11 and half years 
 Implementation of parametric estimation was also the strength of this study  
Limitation of the study 
 As this study was conducted based on secondary data, data on some potentially  
Important predictors were not available. 
 This study was only done among patients who had follow up in university of 
Gondar hospital so it is better to include wide area. 
 The study assumed all the vascular complications are caused by diabetes 
mellitus. 
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8. CONCLUSION 
 
 In this retrospective follow up study we found that the rate of vascular complication 
among type II DM patients in university of Gondar referral hospital was relatively low. 
Hypertension at baseline, LDL-C>100mg/dl, triglyceride >150mg/dl, HDL-C≥40 mg/dl 
and male sex was significant predictors of vascular complication. 
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9. RECOMMENDATIONS 
 
To health professionals: 
-Health professionals should give greater attention to patients with deslipedemia, 
protein urea and hypertension co morbidity together with that of DM 
To the patients 
-Diabetes mellitus patients with hypertension co-morbidity should strictly control the 
hypertension like that of the diabetes 
To researchers 
-Although this research is very useful in understanding vascular complications; there is 
a need of further research on different areas of the countries, by including nutritional 
history, and behavioral factors like level of physical activity, smoking and alcohol 
consumption history. 
-It’s better to us prospective study 
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11. APPENDICES 
Appendix 1: - Information Sheet 
Title of the Research Project: Incidence and risk factors for vascular complication 
among type II DM patients in university of Gondar referral hospital. A retrospective 
follow-up study 
Name of Principal Investigator: Haileab Fekadu 
Name of the Organization: University of Gondar, College Of Medicine and Health 
Sciences, Institute of Public Health 
Sponsor: University of Gondar 
Purpose of the Research Project: The main purpose of this research project is to 
measure vascular complication and its risk factors among Type II DM patients in 
university of Gondar referral hospital. 
Introduction: This information sheet is prepared for University of Gondar referral 
hospital Hospital’s administration and hospitals chronic diseases follow up coordinating 
office. The aim of the form is to make the above concerned offices clear about the 
purpose of research work, data collection procedures and get permission to undertake 
the research. 
Procedure: In order to achieve the above objectives, cards of selected type II DM 
patients who are newly diagnosed between September 2005 and august 2012 will be 
included 
Risk and /or Discomfort: By participating in this research project, there is totally no risk 
that comes to one whom document is reviewed where as the review is of great 
importance to the research project; which is in turn important for overall planning of the 
program. 
Benefits: The research have no direct benefit for one whose document/record is 
included in this research. But the indirect benefit of the research for the participant and 
all other clients in the program is clear. This is because if program planners are 
preparing predicted plan there is a benefit for clients in the program of getting 
appropriate care and treatment services. Of all, the research work has a paramount 
direct benefit for health care planners and managers, especially for those on chronic 
diseases program planning and management 
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Confidentiality: To keep the confidentiality of the records of the clients, the record will 
be extracted by healthcare professionals. Then data collectors will review the selected 
charts. The information collected from this research project will be kept strictly 
confidential and information reviewed about the clients by this study will be stored in a 
file, without name i.e. investigator uses number codes to the record during the review. 
The information gathered will not be accessible to anyone except the principal 
investigator and will be kept locked with password and appropriate locks. 
Person to contact: This research project will be reviewed and approved by the 
Institutional Review Board of College of Medicine and Health Sciences, University of 
Gondar. If in case you want to know more information about the research and its 
undertakings, you can contact the committee through the address of the advisor and/or 
the principal investigator below. 
1. Dr. Asrat Atsedeweyen (PhD), University of Gondar, College of Medicine and 
Health Sciences, Institute of Public Health, Department of Epidemiology and 
Biostatistics: Advisor   Tel: +251-930001197 
2. Mr. Adissu Jember (Msc): Gondar University, College of Medicine and Health 
Sciences, Institute of Public Health, Department of Epidemiology and Biostatistics: 
Advisor  Tel: +251-945014569  
3. Haileab Fekadu: University of Gondar, College of Medicine and Health 
Sciences, Institute of Public Health, Department of Epidemiology and 
Biostatistics: principal investigator 
Tel: +251-918-255964 e-mail: haileabfekadu@gmail.com 
Permission: Lastly but not least, you are kindly requested to permit and forward your 
Permission to concerned body in your organization so that the researchers can get 
Cooperation from the data clerks and other responsible bodies in place. 
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Appendix 2: Data collection Check list 
This checklist is prepared for the collection of socio-demographic, clinical, treatment and outcome related information that are important for the assessment of 
outcome and predictors of vascular complication of DM in University of Gondar Hospital. All this information will be retrieved from individual patient card without 
mentioning the name of clients. This information will be collected by health care providers (BSc nurse or Health Officer) possibly working in chronic diseases follow 
up clinic.  Contact Information   Haileab Fekadu +251918255964  
S.No Variables  Categories       
01 Patient MRN number       
02 Age  ________yer       
03 Gender  0.  Female                   1. Male    
04 Residence 0. Rural                             2. Urban     
05 Occupation  0.Unemployed                    1.Government                       2.Nongovernment                       3. Private        
06 Family history of DM   0.yes               1.No     
07 Date of diagnosis _______/______/______ 
  08 FBG level  ______________   Mg/dl 
  09 Weight _________Kg                                    Ht_________mt 
  10 Treatment start date ________/_______/_______ 
  11 Type of treatment 0.  OHA                         1.    Insulin                         2.   OHA and insulin 
  12 Duration of diabetes _________yer 
  13 R. SBP ________mm/hg 
  14 R. DBP ________mm/hg 
   15 Protein urea 0. Negative                     1.   Positive                      
  16  Creatinine level  _________ __ml/s 
  17 HDL -C   __________mg/dl 
   18 LDL-C __________mg/dl 
  19.  T. cholesterol _________mg/dl 
   20 Triglyceride __________mg/dl        
  21 Hypertension 1. Yes                                        2. No 
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 22 Vascular complication  
1. Retinopathy  ---------/---------/--------                             2. Nephropathy  --------/-------/-------        
 
 3. Neuropathy------/-----/----                                              4 .  Stroke    -------/--------/----- ----        
 
5.  CHD    ------/-----/----                                                     6. PAD  ------/-----/----                           7. No 
  23 Diagnosis time for the 
first event 
 
---------/--------/---------- 
  24 Last status of patient  
1. Lost follow-up---------/-------/--------            2. Died --------/---------/---------     
 
2. Alive                                                             4. Transferred out                                                   5. Other 
 
Baseline measurements 
Date (D/M/Y) FBS SBP DBP Protein urea Complication Creatinine  Treatment 
        
 
Collected by: Name _________________________ Signature ____________Date ________________ 
Supervised by: Name _______________________ Signature ____________ Date _______________ 
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Appendix- 3 
Table1: Interactions of each of the covariates with time among type II DM patients in 
university of Gondar referral hospital September, 2005 to August, 2012. 
Variables Hazard ratio    Std. err  P-value          95% CI 
Age*t 1.000296 0.0003177  0.351 0.999674,  1.000919 
Sex*t 1.003787 0.0081563  0.642 0.9879272,  1.019901 
Residence*t 1.009742 0.0106959  0.360 0.988945,  1.030924 
Occupation*t 1.001665 0.0034266  0.627 0.994971,  1.008403 
Family history*t 1.009614 0.0074468  0.195 0.9951231,  1.024315 
Protein urea*t 1.012375 0.007577  0.100 0.997633,   1.027335 
Treatment type*t 1.001776 0.005004  0.722 0.9920162,  1.011632 
Creatinine*t 1.004912 0.0044586  0.269 0.962113,  1.013689 
HTN*t 1.000375 0.0118728  0.975 0.977373,  1.023918 
HDL*t 0.9864459 0.0080768  0.096 0.970742,  1.002404 
LDL*t 0.9970929 0.0110624  0.793 0.9756452,  1.019012 
Triglyceride*t 1.015449 0.0110133  0.157 0.9940911,  1.037266 
Cholesterol*t 1.015074 0.0084022    0.071 0.9987383,  1.031676 
BMI*t 1.001824 0.0046514  0.695 0.9927487,  1.010982 
FBS*t 1.000095 0.00004466    0.342 0.99922,   1.0009708 
SBP*t 0.9999026 0.0001784  0.585 0.9995531,  1.000252 
DBP*t 0.9999532 0.0003738  0.900 0.9992208,  1.000686 
Table2: test of proportional hazard assumption based on schoenfold residuals for 
the covariates among type II DM patients in university of Gondar referral hospital 
September 2005 to August 2012. 
Variable rho Chi-square df P-value 
Age 0.05130 0.29 1 0.5882 
Sex -0.01568 0.02 1 0.8831 
Residence -0.00413 0.00 1 0.9625 
Occupation 0.03662 0.14 1 0.7070 
Family history 0.11395 1.55 1 0.2132 
Protein urea -0.03467 0.17 1 0.6828 
Treatment type -0.02113 0.05 1 0.8253 
Creatinine 0.02624 0.07 1 0.7937 
HTN 0.05382 0.35 1 0.5518 
HDL-C -0.16743 1.92 1 0.2265 
LDL-C -0.14251 2.38 1 0.1228 
Triglyceride 0.05208 0.41 1 0.5214 
Cholesterol 0.12571 2.06 1 0.1512 
BMI -0.05820 0.38 1 0.5398 
FBS 0.08971 0.93 1 0.3343 
SBP -0.04533 0.17 1 0.6826 
DBP -0.15322 2.44 1 0.1185 
Global test  16.37 17 0.5102 
46 
 
Appendix 4 
Figure: Plots of Kaplan-Meier survivor functions based on different factors, of type II DM 
patients under ant diabetic’s treatment in university of Gondar referral hospital 
September, 2005 – August, 2012. 
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Appendix 5 
Figure: Cox-Snell residuals obtained by fitting exponential, Weibull and Gompertz 
models for type II DM patients under ant diabetic’s treatment in University of Gondar 
Referral hospital September, 2005 – August, 2012 
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Appendix 6 
Figure: –log(log(Survival probability) VS log (Survival time) plot for different 
categorical covariates among type II DM patients in university of Gondar referral 
hospital September 2005- August 2012. 
A.                                                                        B.  
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